We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

35 hedge funds and large institutions have $43.2M invested in Aquestive Therapeutics in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.86% less ownership

Funds ownership: 58.11% → 54.25% (-3.9%)

13% less funds holding

Funds holding: 40 → 35 (-5)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

29% less capital invested

Capital invested by funds: $61M → $43.2M (-$17.8M)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
8
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$334K
2
OAM
Oxford Asset Management
United Kingdom
+$182K
3
Two Sigma Investments
Two Sigma Investments
New York
+$156K
4
TRCT
Tower Research Capital (TRC)
New York
+$111K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$106K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$2.48M
2
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$673K
3
Millennium Management
Millennium Management
New York
-$622K
4
Northern Trust
Northern Trust
Illinois
-$314K
5
PP
Paloma Partners
Connecticut
-$213K
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
26
Marshall Wace North America
New York
$26K +$30.3K +8,100 New
Morgan Stanley
27
Morgan Stanley
New York
$13K -$49.8K -13,293 -77%
AG
28
Advisor Group
Arizona
$12K +$13.9K +3,706 New
Victory Capital Management
29
Victory Capital Management
Texas
$10K +$11.8K +3,148 New
BNP Paribas Financial Markets
30
BNP Paribas Financial Markets
France
$4.45K – – –
Wells Fargo
31
Wells Fargo
California
$3K -$58.6K -15,646 -94%
Citigroup
32
Citigroup
New York
$2K -$1.34K -359 -35%
Barclays
33
Barclays
United Kingdom
$2K +$1.47K +391 +93%
Daiwa Securities Group
34
Daiwa Securities Group
Japan
$1K – – –
EWM
35
Edge Wealth Management
New York
$1K – – –
OM
36
Opaleye Management
Massachusetts
– -$2.48M -590,000 Closed
PP
37
Paloma Partners
Connecticut
– -$213K -50,700 Closed
Jane Street
38
Jane Street
New York
– -$133K -31,597 Closed
Canada Pension Plan Investment Board
39
Canada Pension Plan Investment Board
Ontario, Canada
– -$105K -25,000 Closed
Bank of America
40
Bank of America
North Carolina
– -$56K -13,307 Closed
TAM
41
Tiverton Asset Management
Delaware
– -$45K -10,742 Closed
Deutsche Bank
42
Deutsche Bank
Germany
– -$15K -3,957 Closed
FCM
43
Flinton Capital Management
Pennsylvania
– -$15K -3,604 Closed
TAM
44
Tyers Asset Management
Texas
– -$13K -2,968 Closed
NA
45
Neuburgh Advisers
California
– -$10K -2,332 Closed
Legal & General Group
46
Legal & General Group
United Kingdom
– -$9K -2,050 Closed
MCIM
47
Meadow Creek Investment Management
Georgia
– -$7K -1,696 Closed
1
2

AQST Hedge Fund Activity: Q3 2019 in Review

35 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2019, worth a combined $43.2M — down 29% from $61M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of AQST and 8 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was JP Morgan Chase, adding an estimated $334K. The largest seller was Opaleye Management, exiting entirely with an estimated $2.48M sold.

  • 35 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2019, down from 40 in Q2 2019.
  • Funds reported $43.2M of Aquestive Therapeutics stock for Q3 2019, down 29% quarter-over-quarter.
  • 8 funds opened new Aquestive Therapeutics positions in Q3 2019 and 13 closed out, a net change of -5 holders.
  • The largest Aquestive Therapeutics buyer in Q3 2019 was JP Morgan Chase, an estimated $334K added.
  • The largest Aquestive Therapeutics seller in Q3 2019 was Opaleye Management, an estimated $2.48M sold.

Based on aggregated 13F filings for Q3 2019.